I am an investor

Read more

I want to know more about
Cantargia's research

Read more

I want to know more about
Cantargia as a company

Read more

CEO Interview

To the interview (In Swedish)

CEO presentation AGM

To the presentation (In Swedish)

Cantargia R&D Day

To the presentation

CEO interview

To the interview (in Swedish)

Cantargia in a panel discussion on how to build a successful biotech company

Panel discussion (in Swedish)

Press releases

2021-07-01 (R) Cantargia advances development of nadunolimab in triple negative breast cancer through submission of clinical protocol for TRIFOUR study

2021-07-01 (R) Cantargia advances development of nadunolimab in triple negative breast cancer through submission of clinical protocol for TRIFOUR study

2021-06-29 (R) Cantargia broadens the development of nadunolimab in three forms of cancer and submits application for the phase I/II clinical trial CESTAFOUR

(R) = Regulatory press releases

”Looking back at the past year, Cantargia now stands on even firmer ground than we did a year ago, despite everything. We have made progress both on our main project, CAN04, and on our second project, CAN10.”

Göran Forsberg

CEO Cantargia

Analysis

2021-05-27, Nordea analysis of Cantargia

2021-04-06, Edison analysis of Cantargia

2021-03-10, Edison analysis of Cantargia

2021-02-26, Nordea analysis of Cantargia

Presentations

2021-06-29, Presentation, LifeSci Advisors Nordic BioTech Summit

2021-06-07, Video, Aktiespararna, Småbolagsdagarna 2021 (In Swedish)

2021-06-07, Presentation, Aktiespararna, Småbolagsdagarna 2021

2021-06-02, Video, Redeye Growth Day 2021 (In Swedish)

© Copyright 2021 · Cantargia AB